Trial Profile
A Phase I/II Study to Determine Feasibility and Safety MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jul 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Copanlisib
- Indications Anaplastic large cell lymphoma; Extranodal NK-T-cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2022 Status changed from active, no longer recruiting to discontinued.
- 07 Oct 2020 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
- 07 Oct 2020 Status changed from recruiting to active, no longer recruiting.